Phase 2 trial data put retatrutide ahead of every approved weight-loss drug on the market. 24.2% mean body weight reduction at 48 weeks — outperforming semaglutide and tirzepatide by a wide margin. The compound is not approved yet. That’s exactly why it matters now.
Retatrutide (development code LY3437943) is Eli Lilly’s next-generation peptide for obesity and metabolic disease. Where semaglutide is a single-agonist and tirzepatide is a dual-agonist, retatrutide is a triple-agonist — hitting GLP-1, GIP and glucagon receptors simultaneously. The trial results have been called the most significant pharmaceutical weight-loss data in a decade.
This guide breaks down what retatrutide actually is, what the trials show, how it compares to current standards, and what we know — and importantly, what we still don’t know — about dosing, side effects and availability.
The triple-agonist mechanism — what’s different
To understand why retatrutide hits harder than tirzepatide, you have to understand what the third receptor adds.
- GLP-1 receptor agonism — appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion. This is the foundation of semaglutide.
- GIP receptor agonism — enhanced insulin secretion, lipid metabolism improvements, additive appetite effects. This is what tirzepatide adds.
- Glucagon receptor agonism — increased energy expenditure, hepatic fat oxidation, mobilization of stored energy. This is the third lever retatrutide pulls.
The glucagon arm is the critical addition. Classic glucagon raises blood glucose — but in the context of simultaneous GLP-1 and GIP activation, the metabolic effect flips. Energy expenditure increases without the hyperglycemia risk you’d expect from glucagon alone. The net result: a compound that both reduces intake (appetite suppression) AND increases output (metabolic rate). Semaglutide and tirzepatide only do the first.
Phase 2 trial data — the numbers that changed the field
The landmark Phase 2 trial published in the New England Journal of Medicine in 2023 tested retatrutide in 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities. Participants were randomized to placebo or one of four retatrutide doses (1 mg, 4 mg, 8 mg, 12 mg) administered weekly.
Mean body weight reduction at 48 weeks
| Dose | Weight loss at 48 weeks |
|---|---|
| Placebo | 2.1% |
| 1 mg | 8.7% |
| 4 mg | 17.1% |
| 8 mg | 22.8% |
| 12 mg | 24.2% |
For context: semaglutide 2.4 mg produced 14.9% weight loss in STEP-1 at 68 weeks. Tirzepatide 15 mg produced 22.5% in SURMOUNT-1 at 72 weeks. Retatrutide hit 24.2% at 48 weeks — faster onset and higher ceiling, in the same patient population.
More telling: the weight-loss curve had not plateaued at 48 weeks. Participants were still actively losing weight when the trial ended. This is rare in GLP-1 trials, where plateaus typically appear between weeks 30 and 50.
Retatrutide vs tirzepatide vs semaglutide — direct comparison
| Metric | Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg |
|---|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Mean weight loss | 14.9% (68 wk) | 22.5% (72 wk) | 24.2% (48 wk) |
| ≥20% weight loss | ~32% of patients | ~57% of patients | ~83% of patients |
| Plateau onset | ~30 weeks | ~40 weeks | Not reached at 48 weeks |
| Half-life | ~7 days | ~5 days | ~6 days |
| Dosing | Weekly | Weekly | Weekly |
| Approved (US/EU) | Yes | Yes | Not yet |
The 83% figure for ≥20% weight loss on retatrutide is the number that pharmaceutical analysts keep highlighting. For more than four out of five patients to lose at least one-fifth of their body weight is unprecedented for a single compound.
Side-effect profile — what to expect
Retatrutide’s GI side effects in trials were similar in pattern to other GLP-1 agonists — nausea, diarrhea, constipation, vomiting — and similar in intensity to tirzepatide. Most events were mild-to-moderate and occurred during titration.
| Side effect | Frequency (12 mg dose) |
|---|---|
| Nausea | ~33% |
| Diarrhea | ~26% |
| Vomiting | ~15% |
| Constipation | ~14% |
| Increased heart rate | +5-8 bpm (mean) |
The one signal distinct from current GLP-1 agonists is a modest mean increase in heart rate (5–8 bpm). This is attributed to the glucagon agonism — glucagon has direct cardiovascular effects. Whether this matters long-term is a question Phase 3 trials are designed to answer.
Dosing schedule — what we know so far
The Phase 2 trial used standard titration:
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 2 mg | Tolerance phase |
| 5–8 | 4 mg | First therapeutic step |
| 9–12 | 8 mg | Step-up |
| 13+ | 12 mg | Target maintenance |
Titration is mandatory. The compound is too strong for users to start at a therapeutic dose — GI side effects will end the cycle before benefits accrue. Treat titration as non-negotiable.
What we don’t know yet
Honest summary of the gaps:
- Long-term safety (5+ years). Phase 2 followed patients for 48 weeks. The cardiovascular outcomes trial is ongoing — results expected 2026–2027.
- Body composition. Total weight loss is impressive. The fat-to-lean ratio of that loss is not fully characterized yet. Early signals suggest similar lean-mass loss to tirzepatide, but more data is needed.
- Weight regain after discontinuation. Both semaglutide and tirzepatide show significant regain after stopping. Retatrutide is likely no different — but the steepness of the regain curve is unknown.
- Maintenance dosing strategy. What dose maintains weight after reaching target? No trial data yet.
Availability — when does retatrutide hit the market?
Phase 3 trials (TRIUMPH program) are in progress. The earliest plausible FDA approval window is 2026–2027 for obesity, with diabetes and metabolic indications likely following. EMA approval typically trails FDA by 6–12 months.
Until approval, retatrutide is available only as a research compound. This is the standard pre-approval pattern for every peptide that later became standard of care — semaglutide, tirzepatide and retatrutide all went through this phase.
The verdict — is retatrutide the new weight-loss king?
On the trial data alone, yes. No approved or experimental compound currently matches retatrutide’s combination of weight-loss depth, response rate and metabolic improvements. The triple-agonist mechanism is a fundamental step forward from dual-agonist therapy.
But “king” is a function of more than peak performance. Long-term safety, real-world tolerability, cost, and weight maintenance after cycle completion are all unanswered. Tirzepatide remains the proven, available choice for users who want maximum effect with full safety data.
Retatrutide is the future. Tirzepatide is the present. Semaglutide remains the entry point for users who want a proven, gentler protocol. Pick the compound that matches both your goal and the data you’re comfortable with.